[Extended protection with Efmoroctocog alfa].
作者信息
Meißner Thomas
出版信息
MMW Fortschr Med. 2016 Jun 23;158(12):74.
PMID:27462665
Abstract
摘要
相似文献
1
[Extended protection with Efmoroctocog alfa].
MMW Fortschr Med. 2016 Jun 23;158(12):74.
2
Continuous infusion of extended half-life factor VIII (efmoroctocog alpha) for surgery in severe haemophilia A.
Haemophilia. 2018 Jul;24(4):e280-e283. doi: 10.1111/hae.13557. Epub 2018 Jul 25.
3
Efmoroctocog Alfa: A Review in Haemophilia A.
Drugs. 2021 Nov;81(17):2035-2046. doi: 10.1007/s40265-021-01615-w. Epub 2021 Nov 7.
4
Switching to extended half-life products in Canada - preliminary data.
Haemophilia. 2017 Jul;23(4):e365-e367. doi: 10.1111/hae.13245. Epub 2017 May 26.
5
Efmoroctocog Alfa: A Review in Haemophilia A.
Drugs. 2016 Sep;76(13):1281-1291. doi: 10.1007/s40265-016-0622-z.
6
Eloctate for hemophilia A.
Med Lett Drugs Ther. 2015 Oct 12;57(1479):143-4.
7
[Switching toward the use of recombinant factor VIII Fc fusion protein Study among 30 patients with severe hemophilia A].
Ann Biol Clin (Paris). 2020 Feb 1;78(1):35-46. doi: 10.1684/abc.2020.1520.
8
Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.
Blood. 2012 Mar 29;119(13):3031-7. doi: 10.1182/blood-2011-09-382846. Epub 2012 Jan 5.
9
Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective.
BMC Health Serv Res. 2018 Aug 2;18(1):596. doi: 10.1186/s12913-018-3398-x.
10
New hemophilia A treatment allows less-frequent prophylactic doses.
Am J Health Syst Pharm. 2014 Jul 15;71(14):1153. doi: 10.2146/news140048.
引用本文的文献
1
Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Real Life: One-Year Clinical and Economic Outcomes.
Drugs Real World Outcomes. 2021 Dec;8(4):527-535. doi: 10.1007/s40801-021-00259-2. Epub 2021 Jun 25.
Zotero 插件